A recent study has investigated the combination of transarterial chemoembolization (TACE), lenvatinib (a tyrosine kinase inhibitor), and anti-PD-1 antibodies, which has shown promising results in converting unresectable HCC to resectable status (117). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.